Search Results
Your search for ,OUr matches 10645 pages
Showing 251 - 300Is TBI Associated With Malignant Brain Tumors?
The results of a retrospective cohort study published in JAMA Network Open revealed an association between having a history of moderate to severe traumatic brain injury (TBI) and the risk of developing malignant brain tumors in adult civilians from the United States. Marini et al confirmed the...
ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings
On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...
JCO Authorship Guidelines Are of Benefit to Those Caring for Older Patients
The aging population, now the largest group of patients with cancer and cancer survivors, requires a rigorous and focused approach to clinical trial reporting, a need highlighted by the recent author guidelines from the Journal of Clinical Oncology (JCO; Table 1).1 The guidelines are an important...
Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer
Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medications that are associated with increased frailty at the time of their cancer diagnosis, according...
New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow
The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...
Is IFITM3 a Driver of Immunotherapy Response in SCLC?
New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. These findings were presented at the...
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...
Hypofractionated Radiotherapy Plus Concurrent Chemotherapy vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...
Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in Unresectable Stage III NSCLC
Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...
Jeffrey A. Drebin, MD, PhD, Named Chief Physician Executive of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Jeffrey A. Drebin, MD, PhD, has been named Chief Physician Executive. A renowned surgeon-scientist, Dr. Drebin previously served as Chair of the Department of Surgery and brings decades of leadership and clinical experience...
‘A Playbook for Best Practices’: ASCO and COA Release Updated Oncology Medical Home Standards
ASCO and the Community Oncology Alliance (COA) have released updated standards for its Oncology Medical Home (OMH) certification program, which were initially codified and published in 2021.1 The 2021 systematic literature review focused on the topics of OMH model of care, clinical pathways, and...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
Urine-Based Biomarker Panel for the Detection of Prostate Cancer
A novel, urine-based, three-biomarker panel demonstrated significant accuracy and promising sensitivity and specificity for the detection of prostate cancers during development and validation testing, according to findings published in eBioMedicine. “This new biomarker panel offers a promising,...
A Year of Global Progress Against Cancer—and Persistent Challenges
Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...
Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?
Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...
Could a Nasal Spray Help Protect Patients With Cancer Against COVID-19 Infection?
Use of a daily interferon-α nasal spray could significantly reduce the risk of COVID-19 infection among adult patients with cancer, according to the results of a multicenter, randomized trial published in Clinical Infectious Diseases. The results suggest that the nasal spray could be a potential...
New Report on Breast Reconstruction Preferences Among African American Women
For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery....
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making
This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...
Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer Is Low
For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ. The researchers say this information can help reassure many breast...
IDO1 Inhibition Mitigates Diet-Induced Risk of Cancer-Associated VTE in Preclinical Models
Patients with cancer who have a diet high in tryptophan, or protein-rich foods, have an increased risk for developing cancer-associated venous thromboembolism, according to preclinical findings published in Blood Advances. This increased risk could potentially be mitigated by treatment with an...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With AML
Based on the results of a single-center phase II trial published by Bhatt et al in the American Journal of Hematology, pretreatment geriatric assessment in older adults with acute myeloid leukemia (AML) appeared to be feasible, to identify several functional impairments, to help guide the selection ...
Understanding Accelerated Aging in Survivors of Childhood Cancers
Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...
Gastrointestinal Tumor Microbes May Predict Prognosis and Therapeutic Response
Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment, and those roles make them appealing targets for new therapies. Tumor microbiota–based tools could also help identify high-risk patients and those most susceptible to metastases, and possibly be...
Government Housing Assistance Linked to Reduced Medical Financial Hardship Among Cancer Survivors
Cancer survivors receiving government-subsidized rent were found to have a lower risk of experiencing financial hardships around medical expenses compared with those not receiving housing assistance, according to the results of a cross-sectional study published as a research letter in JAMA Network...
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...
Analysis Shows No Major Racial Differences in Somatic Mutations of Triple-Negative Breast Cancer
A landmark study of the tumor mutational landscape of African American women with triple-negative breast cancer revealed that the mutational profile was largely similar with that of Asian and non-Hispanic White women, except for the presence of TP53 mutations in almost all African American...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
Adding Everolimus to Chemotherapy Reduces Risk for Advanced Triple-Negative Breast Cancer
The addition of everolimus to standard carboplatin chemotherapy led to a 52% reduction in the risk of disease progression or death compared with carboplatin alone in patients with advanced triple-negative breast cancer, according to the results of a randomized phase II trial published in Breast...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, according to findings published in Nature. In exploring the role of perineural invasion and...
Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?
Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...
Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
Can Autoimmune Diseases Increase the Risk of Digestive System Cancer?
In a systematic review and meta-analysis published in the journal eClinicalMedicine, Reizner et al highlighted bias-minimized insights into the associations between autoimmune diseases, such as celiac disease, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes, and the risk of...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination
New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma. Although immunotherapeutics have improved survival for many...
Can a Mitochondrial Antioxidant Drive Metastasis?
Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...
New Report Supports Overhaul of Cancer Drug Dosing
A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies. “The Totality of the Evidence: Optimizing Dosage ...
Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma
The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...
A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...
Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship
Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology. The study highlighted certain challenges in cancer care, including patient-centered coordination and...
New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...
